Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Kalaris Therapeutics Inc
Market Cap
$58.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$58.29M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$58.44M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$57.61M
Gross Margin
100.00%
TTM Avg
50.00%
3Y Avg
-162.98%
5Y Avg
-226.42%
Market Cap
$57.01M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
50.00%
5Y Avg
33.33%
Market Cap
$59.18M
Gross Margin
99.46%
TTM Avg
98.24%
3Y Avg
49.12%
5Y Avg
32.75%
Market Cap
$60.02M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kalaris Therapeutics Inc (KLRS) | $58.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | 0.00% | 0.00% | 0.00% | 0.00% |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | 0.00% | 0.00% | 0.00% | 0.00% |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | 0.00% | 0.00% | 25.00% | 50.00% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | 0.00% | 0.00% | 0.00% | 0.00% |
| Talphera, Inc. (TLPH)vs › | $57.61M | 100.00% | 50.00% | -162.98% | -226.42% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | 100.00% | 100.00% | 50.00% | 33.33% |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | 99.46% | 98.24% | 49.12% | 32.75% |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | 0.00% | 0.00% | 0.00% | 0.00% |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
